Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

NCT06131021
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases, Periodontal Pocket
Interventions
Amoxicillin, Metronidazole, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

NCT05295628
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Interventions
EMBLOK™ Embolic Protection System ("EMBLOK EPS"), SENTINEL™ Cerebral Protection System
Device
Lead sponsor
Emblok, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Chandler, Arizona • Orange, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 20, 2026, 11:16 AM EDT
Recruiting Phase 2 Interventional

Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD

NCT06608277
View directory record Official record
Conditions
Posttraumatic Headache, Posttraumatic Stress Disorder
Interventions
Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
Procedure · Drug · Combination Product + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Environmental and Acceptance-Based Innovations for Weight Loss Maintenance

NCT01858714
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Behavior Therapy for Weight Loss, Behavior Therapy + Environment, Acceptance-based Behavior Therapy + Environment
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 70 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking

NCT00218465
View directory record Official record
Conditions
Nicotine Dependence
Interventions
GW468816, Placebo Comparator: Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

NCT02265744
View directory record Official record
Conditions
Lupus
Interventions
BMS-931699, Placebo matching BMS-931699
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
25
States / cities
Huntsville, Alabama • Fullerton, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 20, 2026, 11:16 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

NCT07687784
View directory record Official record
Conditions
Iron Deficiency Anemia (IDA)
Interventions
Ferric Bepectate IV Injection, Ferric Carboxymaltose Injection [Ferinject], Ferric Carboxymaltose Injection [Injectafer®]
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Coral Gables, Florida • Melbourne, Florida • The Villages, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474
View directory record Official record
Conditions
Wounds
Interventions
Placebo gel, GLYC-101 gel (1.0 %)
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

NCT01964989
View directory record Official record
Conditions
Influenza Virus
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 71 Months
Enrollment
10,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
91
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 20, 2026, 11:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes

NCT07015047
View directory record Official record
Conditions
Recovery of Function (G11.427.698.620), Athletic Performance, Heart Rate Variability (HRV)
Interventions
Magnesium L-Threonate, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

NCT05405660
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
barzolvolimab, Matching Placebo
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Spectra Optia CMNC Collection Procedure

NCT02253160
View directory record Official record
Conditions
Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
Interventions
Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF)
Device · Drug
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 3 Interventional

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

NCT00660959
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume
Interventions
lixivaptan, placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 20, 2026, 11:16 AM EDT
Not yet recruiting Phase 1 Interventional

Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care

NCT07456150
View directory record Official record
Conditions
Chronic Pain, Musculoskeletal Pain
Interventions
Coaching
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2029 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 3 Interventional

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

NCT00676507
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions
Lucanix™, Placebo Comparator
Biological · Other
Lead sponsor
NovaRx Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
53
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 20, 2026, 11:16 AM EDT
Suspended Phase 2Phase 3 Interventional

Ankle Manual Therapy for Ankle Sprains

NCT00888498
View directory record Official record
Conditions
Sprains and Strains
Interventions
Passive Positioning, High-Velocity, Low-Amplitude Stretch, Slow, Mobilization Stretch
Other
Lead sponsor
University of the Pacific
Other
Eligibility
16 Years to 60 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Attention Training for Underserved Youth With Anxiety

NCT03028792
View directory record Official record
Conditions
Anxiety
Interventions
Attention Modification Program, Attention Control Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
El Centro, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 20, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks

NCT00207194
View directory record Official record
Conditions
Hypertension
Interventions
Automated Telephone Program, Health Behavior Education
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
35 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 20, 2026, 11:16 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

NCT06942520
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
Genetic · Biological
Lead sponsor
Sierra Eye Associates
Other
Eligibility
25 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 20, 2026, 11:16 AM EDT